GlassScriptPhysician profile
Kaupin Brahmbhatt
NPI 1447227756
$12,619.78
in general payments reported to CMS, 2019-2025
34 companies · $1,754 in 2025
The $1,754 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,068 · 2020: $652 · 2021: $1,629 · 2022: $2,576 · 2023: $2,516 · 2024: $2,424 · 2025: $1,754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,694 · Education: $0.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,693.88 |
| Education | $0.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,673.03 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,018.24 | 2019-2025 | Farxiga, Wainua |
| Amgen INC. | $966.92 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $857.42 | 2019-2025 | Jardiance |
| Pfizer INC. | $805.33 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $728.23 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $699.20 | 2021-2025 | Verquvo |
| Abbott Laboratories | $678.82 | 2019-2025 | Aveir, Mitraclip, Thoratec Heartmate 3 Lvas Implant Kit |
| Sanofi-Aventis U.S. LLC | $677.55 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $638.55 | 2022-2025 | Eliquis, Camzyos |
| Boston Scientific Corporation | $627.09 | 2019-2025 | Watchman Flx, Watchman Access System, Cds - Mct/Cem Monitoring |
| Esperion Therapeutics, INC. | $583.33 | 2020-2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $418.85 | 2022-2024 | Xarelto |
| Novo Nordisk INC | $410.88 | 2022-2025 | Ozempic, Rybelsus |
| Regeneron Healthcare Solutions, INC. | $231.32 | 2019-2024 | Evkeeza, Praluent |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $231.14 | 2023-2024 | Inpefa |
| Daiichi Sankyo INC. | $222.86 | 2023-2025 | Injectafer |
| Kowa Pharmaceuticals America, INC. | $156.52 | 2019-2022 | |
| Scpharmaceuticals INC. | $156.41 | 2024-2025 | |
| Heartflow, INC. | $121.26 | 2024-2025 | |
| Althera Pharmaceuticals LLC | $113.26 | 2021-2022 | |
| Lilly USA, LLC | $92.67 | 2025 | Zepbound |
| Kestra Medical Technology Services, INC. | $83.86 | 2022-2023 | Assure Wcd |
| Impulse Dynamics (USA) INC. | $77.10 | 2021-2022 | |
| Kiniksa Pharmaceuticals, LTD. | $58.43 | 2023 | Arcalyst |
| Chiesi USA, INC. | $46.28 | 2019-2024 | Kengreal, Cleviprex |
| Astellas Pharma US INC | $44.83 | 2019-2020 | |
| Kiniksa Pharmaceuticals International, Plc | $43.33 | 2024 | Arcalyst |
| Vifor Pharma, INC. | $37.54 | 2019 | |
| Alnylam Pharmaceuticals INC. | $36.05 | 2025 | Amvuttra |
| Lundbeck LLC | $33.76 | 2019 | |
| Bridgebio Pharma, INC. | $19.30 | 2025 | Attruby |
| Arbor Pharmaceuticals, INC. | $17.75 | 2019 | |
| Gilead Sciences, INC. | $12.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaupin Brahmbhatt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.